{
    "organizations": [],
    "uuid": "4199589273b2d5772075d2ef688a5d1e293b43ce",
    "author": "",
    "url": "https://www.reuters.com/article/brief-abbvie-announces-positive-results/brief-abbvie-announces-positive-results-from-second-phase-3-study-of-elagolix-in-women-with-uterine-fibroids-idUSFWN1QV0N4",
    "ord_in_thread": 0,
    "title": "BRIEF-Abbvie Announces Positive Results From Second Phase 3 Study Of Elagolix In Women With Uterine Fibroids",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 13, 2018 / 12:27 PM / in 13 minutes BRIEF-Abbvie Announces Positive Results From Second Phase 3 Study Of Elagolix In Women With Uterine Fibroids Reuters Staff 1 Min Read March 13 (Reuters) - Abbvie Inc: * ABBVIE ANNOUNCES POSITIVE TOPLINE RESULTS FROM SECOND PHASE 3 STUDY EVALUATING INVESTIGATIONAL ELAGOLIX IN WOMEN WITH UTERINE FIBROIDS * ABBVIE INC - ‍SECOND OF TWO PIVOTAL PHASE 3 STUDIES (ELARIS UF-II) MET PRIMARY EFFICACY ENDPOINT AND ALL RANKED SECONDARY ENDPOINTS​ * ABBVIE INC - ‍RESULTS WERE CONSISTENT WITH FIRST PHASE 3 STUDY​ * ABBVIE INC - STUDY ALSO MET ALL RANKED SECONDARY ENDPOINTS (P<0.02) AT MONTH SIX * ABBVIE INC - ‍RESULTS DEMONSTRATED ELAGOLIX, WITH LOW-DOSE ADD-BACK THERAPY, REDUCED HEAVY MENSTRUAL BLEEDING COMPARED TO PLACEBO​ * ABBVIE INC - ‍WOMEN IN STUDY WILL CONTINUE IN EITHER POST-TREATMENT FOLLOW-UP OR A BLINDED SIX-MONTH EXTENSION STUDY​ Source text for Eikon: Further company coverage:",
    "published": "2018-03-13T14:26:00.000+02:00",
    "crawled": "2018-03-13T14:42:54.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "minute",
        "announces",
        "positive",
        "result",
        "second",
        "phase",
        "study",
        "elagolix",
        "woman",
        "uterine",
        "fibroid",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "abbvie",
        "inc",
        "abbvie",
        "announces",
        "positive",
        "topline",
        "result",
        "second",
        "phase",
        "study",
        "evaluating",
        "investigational",
        "elagolix",
        "woman",
        "uterine",
        "fibroid",
        "abbvie",
        "inc",
        "two",
        "pivotal",
        "phase",
        "study",
        "elaris",
        "met",
        "primary",
        "efficacy",
        "endpoint",
        "ranked",
        "secondary",
        "abbvie",
        "inc",
        "consistent",
        "first",
        "phase",
        "abbvie",
        "inc",
        "study",
        "also",
        "met",
        "ranked",
        "secondary",
        "endpoint",
        "p",
        "month",
        "six",
        "abbvie",
        "inc",
        "demonstrated",
        "elagolix",
        "therapy",
        "reduced",
        "heavy",
        "menstrual",
        "bleeding",
        "compared",
        "abbvie",
        "inc",
        "study",
        "continue",
        "either",
        "blinded",
        "extension",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}